$ 2.78
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of PRQR is 9.1 and suggests 228% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
